Stage (next event)
Phase 2 (Data)
Catalyst Info & Data Links
Potential Catalyst Events
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., O'meara, M. J., ... & Kaake, R. M. (2020). A SARS-CoV-2-human protein-protein interaction map reveals drug targets and potential drug-repurposing. BioRxiv.
Perwitasari, O., Johnson, S., Yan, X., Howerth, E., Shacham, S., Landesman, Y., ... & Tripp, R. A. (2014). Verdinexor, a Novel Selective Inhibitor of Nuclear Export, Reduces Influenza A Virus Replication In Vitro and In Vivo. Journal of virology, 88(17), 10228-10243.
HC updated 5/22/20
MECHANISM OF ACTION/RATIONALE
Nuclear export inhibitor
Inhibits XPO1 (see slide 5), which is believed to impact tumor cells in 3 ways
1. Increases nuclear levels and activation of tumor suppressor proteins
2. Traps oncoprotein mRNA in the nucleus leading to reduced oncoprotein levels
3. Retains activated glucocorticoid receptor in the nucleus
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post